legal-document-to-plain-english-translator/”>Try Free Now: Legalese tool without registration

Find a LOCAL lawyer

Tetrous, Inc. Receives Another Patent for EnFix Family of Demineralized Cortical Bone Fiber Implants

LOS ANGELES, Oct. 5, 2023 /PRNewswire/ ÔÇö

Tetrous, Inc., a regenerative medicine company, is excited to announce the issuance of another patent, U.S. Patent Number 11,759,548, by the United States Patent and Trademark Office. This patent specifically relates to the EnFix family of demineralized cortical bone fiber implants and their method of manufacture.

The EnFix RCÔäó, the first product in the EnFix family, is a revolutionary implant designed for rotator cuff repair. Currently available in the United States and Australia, EnFix RC brings a paradigm shift to rotator cuff surgery by enhancing healing at the tendon to bone interface, known as the enthesis. This is where failure often occurs. The implant, made of 100% demineralized bone fiber (DBF), provides both osteoinductivity and osteoconductivity, making it a unique graft. Additionally, the implant incorporates FormLokÔäó technology, which allows it to retain its shape even when immersed in liquid during arthroscopic surgery. This improved biologic repair at the interface between tendon and bone is a significant advancement, and the implant minimizes disruption to the current surgical technique.

The newly issued patent, titled “Demineralized Bone Fiber Implant Compositions and Methods for Rotator Cuff and ACL Repair,” further strengthens Tetrous’ already robust portfolio of intellectual property. It covers demineralized cortical bone fiber implants, bone healing, and enhancement of tendon to bone repair. “We are delighted that the U.S. Patent Office has once again recognized the uniqueness of our technology and has granted us this additional patent,” said Andy Carter, PhD, Tetrous’ Co-Founder, Director, and co-inventor of the issued patent. “Our expanding intellectual property portfolio gives Tetrous a sustainable competitive advantage in the next-generation enthesis repair market.”

How AI legalese decoder Can Help with the Situation

The AI legalese decoder developed by Tetrous, Inc. plays a crucial role in analyzing and decoding complex legal jargon found in patents and other legal documents. With the growing number of patents and intellectual property related to their groundbreaking technology, Tetrous relies on AI legalese decoder to automate the process of extracting key information. This AI-powered tool enhances efficiency and accuracy, ensuring that Tetrous maintains a strong intellectual property portfolio while staying ahead in the competitive market of enthesis repair.

About Tetrous, Inc.

Tetrous, Inc. is a leading regenerative medicine company guided by a team of influential surgeons and regenerative medicine scientists. The company, led by experienced medical device executives, utilizes next-generation advanced technologies for enthesis repair in sports medicine applications. Its first product focuses on improving enthesis repair in rotator cuff surgeries. Founded in 2019, Tetrous is headquartered in Los Angeles, CA, with a service operation in Chicago, IL, and an R&D laboratory in Mammoth Lakes, CA. For more information, visit www.tetrous.com.

The demineralized bone fiber technology used in Tetrous products is exclusively licensed from TheraCell, Inc., an Isto Biologics company, for use in sports medicine.

EnFixÔäó and EnFix RCÔäó are trademarks of Tetrous, Inc.
FormLokÔäó is a trademark of TheraCell, Inc., an Isto Biologics company.